



## **Petra Kaufmann, MD, MSc, FAAN**

### **Vice President R&D Translational Medicine, Av**

Nationality: German

Languages spoken: German, English, French

Dr. Petra Kaufmann is the Vice President, R&D Translational Medicine at AveXis, a Novartis company.

Prior to joining AveXis, Dr. Kaufmann was director of the National Institutes of Health/The National Center for Advancing Translational Sciences (NIH/NCATS) Office of Rare Diseases Research where her work included overseeing the Rare Diseases Clinical Research Network program, Genetic and Rare Diseases Information Center, and the Toolkit for Patient-Focused Therapy Development. Before joining NCATS, Dr. Kaufmann was the director of the Office of Clinical Research at the National Institute of Neurological Disorders and Stroke (NINDS), where she worked with investigators to plan and execute a large portfolio of clinical research studies and trials in neurological disorders. This was where she also launched NeuroNEXT, a trial network to support scientifically sound, biomarker-informed phase 2 trials for neurological diseases in partnership with academia, industry and patient groups.

Dr. Kaufmann has spent most of her career at Columbia University in New York City where she trained in Neurology and was a tenured faculty member. Her research focused on observational studies and trials in mitochondrial diseases and neuromuscular diseases including Spinal Muscular Atrophy (SMA) and Amyotrophic Lateral Sclerosis (ALS).

Dr. Kaufmann has served on scientific advisory boards of numerous national and international organizations and her research has resulted in over 120 publications. A native of Germany, Dr. Kaufmann earned her M.D. from the University of Bonn and her Masters in Biostatistics from Columbia University's Mailman School of Public Health. Dr. Kaufmann is board certified in neurology and neuromuscular medicine.